Clinical Trials
9 trialsNCT07629700 2026-06-05
ENDEAVOR
University of Florence
Phase NA Not yet recruiting
NCT07484022 2026-06-03
Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer
Generate Biomedicines
Phase 1 Recruiting
NCT07548476 2026-05-04
ACE
Dana-Farber Cancer Institute
Phase NA Not yet recruiting
NCT06657157 2026-02-24
P-EVOLUTION
Comprehensive Cancer Center Munich (CCCM)
Recruiting
NCT02921828 2022-07-05
A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg
Celgene
Completed
NCT00369564 2021-08-11
Glutamic Acid in Reducing Nerve Damage Caused by Vincristine in Young Patients With Cancer
University of South Florida
Phase 3 Completed
NCT02492360 2018-02-28
Establishing of Neuronal-like Cells From Patients With Cisplatin-Induced Peripheral Neuropathy
Indiana University
Withdrawn
NCT00365768 2016-09-09
Glutamine in Treating Neuropathy Caused by Vincristine in Young Patients With Lymphoma, Leukemia, or Solid Tumors
Columbia University
Phase 2 Completed
NCT00751205 2014-10-28
Prevention of Sagopilone-induced Neurotoxicity With Acetyl-L-Carnitine (ALC)
Bayer
Phase 2 Completed